As a biological phenomenon the interaction between drugs may be viewed in 'explanatory' or 'empirical' terms. In clinical psychopharmacology the former is rarely possible: two examples are cited, one concerning amphetamine and reserpine, the other desmethylimipramine and tetrabenazine. Among centrally acting substances, empirical studies of the interaction between alcohol and the barbiturates have been pursued intensively by several methods in clinic and laboratory. Both general considerations and recent work on the effects of amphetamine-barbiturate combinations suggest caution in the medical use of mixtures of psychotropic drugs. Adverse reactions caused by interaction between psychotropic drugs and other substances have still to be studied systematically as a potential hazard.
The problems of drug interaction interest, or should interest, clinical psychiatrists for three main reasons. In the first place, they are perhaps more familiar than most clinicians with the issues posed by the general notion of interaction, partly as a statistical concept and partly as a key variable in therapeutics. Since biological, psychological and social factors all play some part in the causation and outcome of most mental illness they have, or should have, learnt to appreciate that it is unwise to view any one therapeutic measure in isolation; and having grasped the importance of interaction between drug therapy and the milieu in which it is administered (Shepherd 1964) , they are unlikely to disregard interaction within the narrower biological field. Secondly, since polypharmacy and its attendant dangers go with clinical ignorance, they can be expected to be rife in a branch of medicine where so much remains to be learnt. Thirdly, psychiatric patients include addicts whose large appetites for drugs afford opportunity for the observation of toxic and other adverse reactions.
In themselves, however, these factors lead principally to a concern with what Schwartz & Lazar (1964) refer to as empirical, as distinct from explanatory, interaction. Empirical interaction, as they point out, can do no more than compare the results obtained by the combination of two or more factors with those obtained by each one separately. The problems are practical; the raw data are observational and may be difficult to interpret. With explanatory interaction, on the other hand, the clinician can hope to make predictions and can employ generalizations drawn from biological mechanisms. In this sphere the direct contribution of the pharmacologist to our knowledge of centrally acting substances appears to be limited at the present time. Sir John Gaddum (1961) , for example, arguing that the most profitable approach to antagonism between centrally acting drugs will depend on experiments in which indirect effects are excluded, has advocated the study of transmission through one particular synapse to which drugs might be applied by iontophoresis. Perhaps he is right, but we are unlikely to see clinical results in the near future. Meanwhile we know something about the complexity of the empirical laws governing druginteraction from the elegant demonstrations of the late Walter Loewe whose isobolograms are best visualized in three dimensions. Loewe's work pays due regard to the multiple effects of single drugs in animals, but it has been applied very little to human subjects and hardly at all to the human central nervous system (Goodman 1964) .
Clearly the scientific map of psychotropic drug interaction is still largely uncharted. I propose, therefore, to refer to a few expeditions in human and clinical pharmacology, chosen as much to underline method as to illustrate achievement.
First, two experiments, both conducted at the Institute of Psychiatry, which employ orthodox pharmacological reasoning to study explanatory interactions, a procedure rare enough in psychopharmacology. The first was with amphetamine, a sympathomimetic am'ine which has been used extensively in psychiatric practice with very little understanding of its central actions in man. In view of the evidence suggesting that its peripheral actions might be related to noradrenaline release, the drug was administered intravenously to normal human subjects who had previously ingested large doses of reserpine in order to deplete their catecholamine stores (Gelder & Vane 1962) . Blood pressure was taken as the principal index of peripheral response and psychological reactions, rated by subject and observer, as a guide to the central action of the drug. The reserpinized subjects who had failed to demonstrate the normal, short-lived hypertensive response to an intravenous injection of 10 mg tyraminepresumably as a result of the depletion of noradrenaline storesnone the less responded to amphetamine in the usual way. Further, after the administration of amphetamine, the characteristic malaise experienced by all the reserpinized subjects was abruptly terminated and replaced by the mildly euphoriant reaction which had been reported in the control period. Seemingly, therefore, neither the peripheral nor the central actions of amphetamine were impaired, and it seems unlikely that either could depend on an intermediary release of noradrenaline.
The second experiment turns on the observation that in rats and mice the reserpine syndrome (hypothermia, profound sedation, muscular rigidity and meiosis) can be inhibited and even reversed by the administration of imipramine. This action is exhibited by anti-depressant drugs related chemically to imipramine and they interact in a similar way with benzoquinolizine derivatives whose effects are similar to those of reserpine. Since the therapeutic action of the tricyclic anti-depressants has not yet been clearly associated with any one of their pharmacological properties, and since these drugs appear to exercise relatively trivial effects on normal man, it seemed reasonable to enquire whether their anti-reserpine and anti-benzoquinolizine actions might not be taken to reflect their anti-depressant action, especially as reserpine is known to induce morbid depression in clinical practice.
For this purpose a group of normal volunteer subjects received intramuscular injections of tetrabenazine followed by an injection of desmethylimipramine (DMI) or placebo (Dick & Shepherd 1965) . The effects of tetrabenazine were assessed by a series of psychophysiological measurements and a specially constructed questionnaire. The results analysed so far suggest that on some of these indices DMI counteracted the initial effect of tetrabenazine. If these results are confirmed, a pharmacological interaction of this type might constitute a useful model both for testing certain new drugs on normal subjects and also for studying the physiopathological mechanisms of depressive states.
Here, then, are two attempts to explore explanatory interactions which are of obvious clinical relevance. At the same time it should be emphasized that the psychiatrist qua clinician encounters chiefly empirical interactions in the clinic, where he is as much concerned with behavioural phenomena as with physicochemical mechanisms. Clinical drug effects are assessed, initially at least and often crudely enough, in behavioural terms.
The scientific evaluation of behaviour in this field, however, has proved difficult even in the case of the intensively studied interaction between alcohol and the barbiturates. Animal studies have yielded conflicting reports on whether these substances produce additive or potentiating effects (Gruber 1955) . Admittedly, there have been individual case reports suggesting fatalities due to potentiation (Jetter & McLean 1943) , but in view of the huge annual consumption of these drugs it is evident that when death occurs in man, it is more likely to be a secondary phenomenon resulting from the impairment of psychomotor coordination necessary for driving a vehicle. It has been maintained that a number of drugs, including isoniazid, amidopyrine, the antihistamines, the opiates, the urea derivatives and the sulphonamides can intensify the noxious effects of alcohol and adversely affect driving ability (Lickint 1956) . A clear demonstration of these interaction effects on human behaviour, however, depends on studies like those of Joyce and his colleagues who have investigated the potentiation of ethyl alcohol by phenobarbitone on standardized tasks under laboratory conditions (Joyce et al. 1959) . Such studies are unfortunately still uncommon, depending as they do on the active collaboration of psychologists who are prepared both to work experimentally with human subjects and to pay due regard to pharmacological principles.
Another approach to the same problem has come from Goldberg (1961) , who has shown with electro-oculographic techniques that horizontal positional nystagmus and horizontal roving ocular movements both occur as after-effects of drinking and continue after alcohol has been eliminated from the blood stream. These responses and their distressing subjective correlates, which include the 'hangover', are demonstrably modified by centrally acting drugs administered with the original dose of alcohol.
The most direct and dramatic clinical studies of alcohol-barbiturate interactions, however, have been those carried out on volunteer addicts at the United States Public Health Service Addiction Centre at Lexington, Kentucky, where the essen-tial similarity of the clinical picture following the sudden withdrawal of large doses of either alcohol or barbiturate was first established (Wikler 1964) . This so-called abstinence syndrome consists of weakness, tremulousness, anorexia, anxiety, insomnia, convulsions and delirium and an attempt was made to induce it by withdrawing one drug and to control it by giving the other. In this way it was possible to demonstrate a partial equivalence between alcohol and barbiturate, which has suggested in turn that the well tried clinical practice of treating the alcoholic abstinence syndrome with cerebral depressants might be regarded as a form of 'substitution' therapy.
The principles of this relatively crude clinical experiment have been refined quantitatively by Isbell (1959) and his colleagues, whose startingpoint has been the similar physical effects and subjective responses obtained with the two psychotomimetic drugs, lysergic acid diethylamide-25 (LSD-25) and psilocybin. Using a 'cross-over' design with subjects acting as their own controls, these workers have shown both that direct tolerance to LSD-25 and psilocybin can be developed and also that subjects rendered tolerant to one drug are cross-tolerant of the other (Isbell et al. 1961) . Other experiments have demonstrated a similar relationship between LSD-25 and mescaline so that evidence exists for cross-tolerance between drugs of similar action but different chemical structure and indicates that they share either a common biological mechanism or a common final pathway (Wolbach et al. 1962 ).
This notion opens up so many possibilities of interaction between centrally acting drugs that caution might be expected to be the rule in the manufacture and prescription of drug mixtures. Unfortunately this is not so. Among such combinations those containing amphetamine and barbiturates are probably the most popular. There are now several preparations available to render the so-called 'purple heart' problem a matter of pharmacological interest as well as of public health concern. Yet, only recently, long after we have known that they are associated with addictive, toxic, psychotic and anti-social phenomena, are we beginning to learn a little about the action of these drug combinations. It has been left to Dr Steinberg and her colleagues (Rushton & Steinberg 1964) to show, not only that the effects of mixtures of amylobarbitone and amphetamine on rats' exploratory behaviour in a Y-maze are in excess of those produced by individual or addictive doses of either drug, but also that similar differences can be demonstrated with normal human subjects. Using amphetamine sulphate and amylobarbitone in two different ratios, one approximating to that employed in the commercial preparation Drinamyl, the other with a much higher proportion of barbiturate, these workers have suggested that the effects of the mixtures on pulse rate, simple tasks and subjective responses differ from those of their constituents, and that of the two combinations the one containing the lower dosage of barbiturate is preferable (Dickins et al. 1965) .
In so far as empirical studies of this type lend experimental support to clinical practice, they are valuable in their own right. It is much to be regretted that so few comparable studies have been conducted on proprietary mixtures of amphetamine with other substances and on combinations of the newer psychotropic drugs. It may be that 'a carefully adjusted combination' of a 'rapid-acting anti-depressant' and a 'versatile tranquillizer' together 'restore the normal resiliency of mood'; or that it is possible both to 'lift depression' and 'calm anxiety' by the joint action of two drugs neither of which is of proven value in the treatment of morbid anxiety or depression. The evidence remains to be produced. Similarly the claim that two phenothiazines are better than one in the control of the major psychoses appears to be based largely on asseveration: I know of only one clinical experiment which purports to test this hypothesis (Talbot 1964) .
Finally, no survey of this subject can nowadays be complete without a word about the adverse effects of drug interaction, which can be useful starting points for research. The monoamine oxidase inhibitors are known to interact adversely with several compounds and already in the first few months the Committee on Safety of Drugs has reports of adverse reactions to other antidepressants and the phenothiazines. It is not possible to assess the significance of these associations at this early stage, but the system opens up important prospects for the future. It is evident that clinical observation has much to offer provided that the observations are systematic and that the frequency as well as the quality of responses can be estimated. Anwsthetists, for example, who premedicate their patients with psychotropic drugs have reported that after the administration of phenothiazines there was, during anesthesia, a potentiation of pethidine, a liability to hypotension and a marked pallor; post-operatively they mention prolonged unconsciousness, hypotension and pallor (Inglis & Barrow 1965) . Since drug consumption has come to constitute one of the distinguishing characteristics of the modern psychiatric patient, the possibilities of a drug-monitoring programme in defined populations (Finney 1965 ) could be profitably explored in this field. It is potentially a rewarding as well as an onerous task. Abstract Monoamine oxidase inhibitors (MAOI) in clinical use have an irreversible action on MAO, and this persists until the enzyme has been resynthesized. The effects of small daily doses of MAOI are therefore cumulative. The biochemical effects of these drugs will involve several substrates of MAO, e.g. dopamine, tyramine, serotonin and, to a lesser extent, noradrenaline and adrenaline.
MAO probably regulates the metabolism of eatecholamlnes and serotonin in tissues, while catechol-O-methyltransferase is responsible for the metabolism of circulating noradrenaline and adrenaline.
Certain pharmacological effects of MAOI are related to the accumulation of monoamines in various tissues that follows the decrease of intraneuronal deamination. Among these effects are reversal of the reserpine syndrome in animals and augmentation of the pharmacological action of monoamines. Other effects are-unrelated to the inhibition of MAO, e.g. immediate desynchronization of EEG and initial pressor effects.
MAOI may potentiate or change the action of several other drugs and even certain foods. The mechanisms involved are usually reasonably predictable from animal experiments. Substrates of MAO, e.g. dopamine and tyramine, evoke augmented and prolonged effects in patients treated with MAOI. This is partly due to an impaired metabolism of the circulating amines. In addition, inhibition of intestinal and hepatic MAO largely increases the absorption of tyramine from cheeses and other foods. Usually innocuous amounts of tyramine may therefore cause hypertensive reactions in patients treated with MAOI. Indirectly acting sympathomimetic amines, such as amphetamines, ephedrine and MAOI with amphetamine-like properties, can be potentiated, because they may release increased amounts of noradrenaline from sympathetic nerve endings after MAO inhibition. The effects of any amine, whether a substrate of MAO or not, may be enhanced by MAO inhibitors producing postganglionic block. This is due to 'denervation' supersensitivity of adrenergic receptors.
Harmful pharmacological interaction is also possible between MAO inhibitors and agents which release (reserpine) or replete (amine precursors, e.g. L-DOPA in broad beans) monoamines centrally and peripherally. Drugs that sensitize adrenergic and tryptaminergic receptors to the action of monoamines, e.g. imipramine-like compounds, may be greatly potentiated by MAO inhibitors. The antihypertensive effects of thiazides and ganglion-blocking agents may be enhanced by MAOI. A few drugs are known to exert prolonged effects in occasional patients treated with MAOI, e.g. pethidine, phenothiazines and pentobarbital. MAOI may possibly decelerate the metabolism of these compounds by a nonspecific inhibition of liver microsomal enzymes. Finally, a great number of agents have been found empirically to evoke augmented effects after inhibition of MAO, e.g. insulin and anti-Parkinson drugs.
The clinically important antidepressive drugs can be classified as either monoamine oxidase (MAO) inhibitors or iminodibenzyl derivatives (imipramine-like drugs). It is impossible to rank individual drugs according to antidepressive efficacy since few meaningful comparative studies have been made. At the most, the evidence from the somewhat controversial literature suggests that imipramine-like drugs are more effective than MAO inhibitors (Cole 1964 , Medical Research Council 1965 and they have, therefore, been recommended as the drugs of choice in the treatment of depression (Medical Letter 1964). According to Cole (1964) both drug groups appear to be significantly superior to a placebo, but no more effective than electroconvulsive therapy. A more recent study failed to demon-
